BNP Paribas Financial Markets Trims Holdings in Halozyme Therapeutics, Inc. $HALO

BNP Paribas Financial Markets cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 81.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 633,529 shares of the biopharmaceutical company’s stock after selling 2,858,457 shares during the quarter. BNP Paribas Financial Markets’ holdings in Halozyme Therapeutics were worth $42,637,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of HALO. Larson Financial Group LLC grew its position in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 343 shares during the period. Clearstead Advisors LLC grew its position in shares of Halozyme Therapeutics by 107.7% in the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 265 shares during the period. Harbour Investments Inc. grew its position in shares of Halozyme Therapeutics by 152.5% in the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 372 shares during the period. Penserra Capital Management LLC purchased a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth about $52,000. Finally, Wexford Capital LP purchased a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth about $70,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $69.82 on Thursday. Halozyme Therapeutics, Inc. has a one year low of $51.06 and a one year high of $82.22. The company’s 50-day moving average is $66.44 and its 200 day moving average is $68.71. The company has a market capitalization of $8.28 billion, a price-to-earnings ratio of 25.12, a price-to-earnings-growth ratio of 0.27 and a beta of 0.88. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.54 by $0.06. The company had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. Halozyme Therapeutics’s revenue for the quarter was up 42.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Sell-side analysts expect that Halozyme Therapeutics, Inc. will post 7.6 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HALO has been the topic of a number of recent research reports. UBS Group reaffirmed a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. HC Wainwright upped their target price on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Finally, Wells Fargo & Company upped their target price on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 19th. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $81.60.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $66.21, for a total transaction of $107,591.25. Following the transaction, the director owned 43,669 shares in the company, valued at approximately $2,891,324.49. This represents a 3.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 20,000 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $67.80, for a total transaction of $1,356,000.00. Following the transaction, the chief operating officer owned 14,366 shares in the company, valued at $974,014.80. This represents a 58.20% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 122,107 shares of company stock worth $8,254,834. Company insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.